Mutants strike again in APL

Blood

Volumn 118, Issue 6, 2011, Pages 1432-1434

  Gallagher, Robert E ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYSTINE; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CANCER REGRESSION; CASE REPORT; DEGRADATION; HUMAN; LIGAND BINDING; MISSENSE MUTATION; NOTE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RELAPSE; SINGLE STRAND CONFORMATION POLYMORPHISM; SUMOYLATION; TACHYPHYLAXIS;

EID: 80051616987     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-357566     Document Type: Note

References (10)

1. Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. MIssense mutations in PML-RARA critical for the lack of responsiveness to arsenic trioxide treatment. Blood. 2011;118(6):1600-1609.
2. Chen SJ, Zhou GB, Zhang XW, Mao JH, de The H, Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood. 2011;117(24):6425-6437.
3. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic- resistant cell lines. Leukemia. 2003;17(5):931-940. (Pubitemid 36626322)
4. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia. 2002;16(10):1940-1958. (Pubitemid 35203437)
5. Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K, et al. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol. 2007;59(4):485-493. (Pubitemid 46122327)
6. Sumi D, Shinkai Y, Kumagai Y. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicol Appl Pharmacol. 2010;244(3):385-392.
7. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 18(1):88-98.
8. Soriano C, Creus A, Marcos R. Arsenic trioxide mutational spectrum analysis in the mouse lymphoma assay. Mutat Res. 2008;646(1-2):1-7.
9. Zhou D-C, Kim S, Ding W, Schulz C, Warrell RP JR, Gallagher RE. Frequent mutations in the ligand binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood. 2002;99(4):1356-1363. (Pubitemid 34547092)
10. Gurrieri C, Nafa K, Merghoub T, Bernardi R, Capodieci P, Biondi A, et al. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood. 2004;103(6):2358-2362. (Pubitemid 38326258)